Event Type
Disclosure
Voluntary
Variant
8-K
, and in Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan
Other Events. On January 6, 2026, the Company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to alixorexton f
Financial Sta tements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1 Press release issued by Alkermes plc dated January 6, 2026. 104 Cove